VANCOUVER, Oct. 14 /PRNewswire/ - CRH Medical Corporation (CRM:TSX-V, CRMMF: OTCQX) announced today that it recently celebrated its 200,000th unique visitor to its online physician marketing platform. The Company began tracking unique visitors when it began the online promotion and referral of patients to its physician network in August 2009.
The Company's proprietary online physician network platform utilizes search engine marketing and optimization strategies to direct patients to its crhsystem.com website. The website provides educational materials for people seeking hemorrhoid information thus enabling them to contact one of the hundreds of physicians listed on the Company's web site. All physicians listed on the CRH website have been trained by the Company in the proper use of CRH's proprietary technology and treatment protocols.
The CRH website is also a source of information for physicians looking to enhance patient care and increase practice revenue. The Company continues to add physicians to its platform and will look for opportunities to maximize the value of this asset in the future.
"Our website and online marketing program provide a valuable platform for CRH and our partners" stated Edward Wright, CRH Chief Executive Officer. "Recently, we have been receiving approximately 20,000 visitors to our website each month. While this growing population of potential customers provides us a means to enhance patient care, the platform also allows us to increase communication and educational opportunities within our physician network. We believe this platform differentiates us from other medical service and product companies in our space and we will continue to explore ways to leverage this asset."
About CRH Medical Corporation:
CRH Medical Corporation is a value added resource to the Gastroenterologist community, providing the CRH O'Regan System™, as well as delivering related, clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web based platform to connect doctors with patients as well as educating its ever increasing install base of physicians. CRH's single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I - IV. The Company's goal is to establish the CRH O'Regan System™ as the standard for hemorrhoid treatment.
The information in this news release contains so-called "forward-looking" statements. These include statements regarding CRH Medical's expectations and plans relating to its business and statements about CRH Medical's expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "CRH Medical believes", "management believes", and similar language. All forward-looking statements are based on CRH Medical's current expectations and are subject to risks and uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may need to raise additional capital to fund future operations; (ii) the policies of health insurance carriers in the United States may affect the amount of revenue the Company receives; (iii) the Company may not successfully market its products; (iv) changes in United States federal or state laws, rules, and regulations, including those governing the corporate practice of medicine, and fee splitting; (v) changes in the United States Anti-Kickback Statute and Stark Law and/or similar state laws, rules, and regulations; (vi) if we are unable to manage growth, we may be unable to achieve our expansion strategy: (vii) our senior management has been key to our growth, and we may be adversely affected if we lose any member of our senior management; (viii) economic dependence on suppliers and our contract manufacturer; (ix) changes in the industry and the economy may affect the Company's business; * evolving regulation of corporate governance and public disclosure may result in additional corporate expenses; (xi) we may not be able to attract Gastroenterologists and other licensed providers to purchase and use the CRH O'Regan System; (xii) we may be subject to competition and technological risk which may impact the price and amount of product we can sell; (xiii) we may not be able to retain sufficient qualified physicians to operate our Centers; (xiv) we may be subject to product liability and medical malpractice claims, which may adversely affect our operations; (xv) our business may be impacted by health care reform in the United States; and (xvi) we may not have the expertise required to expand internationally. CRH Medical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE CRH Medical Corporation